stoxline Quote Chart Rank Option Currency Glossary
  
Virios Therapeutics, Inc. (VIRI)
0.5123  0.042 (9%)    04-12 16:00
Open: 0.4631
High: 0.5276
Volume: 359,261
  
Pre. Close: 0.47
Low: 0.4631
Market Cap: 10(M)
Technical analysis
2024-04-12 4:52:57 PM
Short term     
Mid term     
Targets 6-month :  0.73 1-year :  0.85
Resists First :  0.62 Second :  0.73
Pivot price 0.48
Supports First :  0.41 Second :  0.28
MAs MA(5) :  0.47 MA(20) :  0.44
MA(100) :  0.5 MA(250) :  0.91
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  51.7 D(3) :  47.7
RSI RSI(14): 59.7
52-week High :  2.42 Low :  0.27
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ VIRI ] has closed below upper band by 29.7%. Bollinger Bands are 43.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.53 - 0.53 0.53 - 0.53
Low: 0.46 - 0.46 0.46 - 0.46
Close: 0.51 - 0.51 0.51 - 0.51
Company Description

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.

Headline News

Sat, 13 Apr 2024
Virios Therapeutics, Inc. (NASDAQ:VIRI) Sees Large Growth in Short Interest - Defense World

Tue, 26 Mar 2024
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID - GlobeNewswire

Thu, 29 Feb 2024
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results - Yahoo Finance

Wed, 28 Feb 2024
Virios Therapeutics plans shareholder meeting on stock split - Investing.com

Wed, 28 Feb 2024
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones - GlobeNewswire

Tue, 27 Feb 2024
Virios Therapeutics Enacts Salary Cuts and Grants Stock Options - TipRanks.com - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 19 (M)
Shares Float 17 (M)
Held by Insiders 9.7 (%)
Held by Institutions 8.1 (%)
Shares Short 170 (K)
Shares Short P.Month 152 (K)
Stock Financials
EPS -0.29
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.2
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -54.4 %
Return on Equity (ttm) -95.2 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -5 (M)
Levered Free Cash Flow -3 (M)
Stock Valuations
PE Ratio -1.83
PEG Ratio 0
Price to Book value 2.56
Price to Sales 0
Price to Cash Flow -2.03
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android